Servier and Aitia expand research to fourth area

Aitia, a US biotech using causal AI and Digital Twins in drug discovery and development, is expanding its collaboration with privately-held French drugmaker Servier, to tackle gliomas.

The firms will work together to discover and validate novel drug targets and develop drug candidates for glioma using Aitia's Gemini Digital Twins and Servier's therapeutic discovery and clinical development expertise in oncology. 

This collaboration will include exploration of the heterogeneous biology of these brain cancers, mechanisms of resistance, and drug response at the individual patient level.